In total, 47 consecutive patients with HER2-positive early-stage BC were treated, 24 (51.1%) with sequential anthracyclines and taxanes plus trastuzumab (ATH), 23 (48.9%) with pertuzumab, trastuzumab and taxanes (THP). Here, ERBB2 is linked to breast cancer.